Search results for "CALMET"

showing 10 items of 17 documents

Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

2015

<b><i>Introduction:</i></b> The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. <b><i>Materials and Methods:</i></b> Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. <b><i>Results:</i></b> A total of 411 patients we…

AdultMalemedicine.medical_specialtyUrologyInternational CooperationAntineoplastic AgentsSettore MED/24 - UrologiaMedication AdherenceSocial lifeCohort StudiesRecurrenceInternal medicinemedicineHumansAgedBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgeryClinical PracticeRegimenAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsTreatment interruptionToxicityBCG VaccineDisease ProgressionIntravesical bcgPatient ComplianceFemalenon muscle invasive bladder cancer Bacillus Calmette Guèrin intravesical instillation immunotherapy compliance toxicityNeoplasm Recurrence LocalbusinessCohort studyUrologia internationalis
researchProduct

A new preprocessing tool of ECMWF data for CALMET forecasting simulations

2019

Today, strategies for emergency preparedness, in presence of accidental scenarios in high-risk plants with releases into the atmosphere, have become a priority. To achieve this goal, it is important to have forecast meteorological data in local areas to use in dispersion and transport models and so to respond in advance emergency situations. The paper reports results of research performed to develop a new tool, called FORCALM that is capable to elaborate European Centre for Medium-Range Forecasts (ECMWF) forecast data to use for simulations by CALMET/CALPUFF modeling system. A case study, relevant to an accident occurred in Mediterranean Refinery at Milazzo (Italy), has been examined to val…

Air pollution forecast meteorological data ECMWF CALMET CALPUFF.
researchProduct

Definizione della metodologia e degli input necessari per l’esecuzione di analisi integrate CALMET-CALPUFF ai fini della valutazione della dispersion…

2015

Il presente documento riporta l’attività condotta durante l’ultima annualità dell’AdP ENEAMSE, linea progettuale LP1: “Sviluppo competenze scientifiche nel campo della sicurezza nucleare”, Task B2.3 “Definizione della metodologia e degli inputs necessari per l’esecuzione di analisi integrate Calmet-Calpuff ai fini della valutazione della dispersione di inquinanti radioattivi in atmosfera”. La linea di ricerca si inserisce nell’ambito degli studi condotti dall’ENEA a supporto delle attività di pre-emergenza a seguito di situazioni incidentali in uno degli impianti nucleari dislocati nei Paesi frontalieri dell'Italia.

CALMET CALPUFF dispersione di inquinanti radioattiviSettore ING-IND/19 - Impianti Nucleari
researchProduct

Analisi dei modelli validi per lo studio dei processi di deposizione secca e sui dati meteo previsionali dell’ECMWF

2017

The DEIM's research group in collaboration with ENEA –C.R. Bologna, has performed the following activities: "Analysis of models to study dry deposition processes of pollutants in atmosphere onto urban surface", and "Preliminary study of compatibility between ECMWF forecast data and CALMET model". Regarding the first activity, a dry deposition model, based on electrical analogy, is developed to analyze complex phenomena,such as inertial impact processes and wind turbulence effects, that influence the transport of pollutants in the interface between urban canopy and quasi-laminar sublayer. The model allows the deposition rate assessment for particles with different diameters and various atmos…

ECMWF processi di deposizione secca CALMETSettore ING-IND/19 - Impianti Nucleari
researchProduct

Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microe…

2017

The tumour immune microenvironment is considered to influence cancer behaviour and outcome. Using a panel of markers for innate and adaptive immune cells we set out to characterise and understand the bladder tumour microenvironment of 114 patients from a prospective multicentre cohort of newly-diagnosed bladder cancer patients, followed-up for 4.33±1.71 years. We found IL-17-positive cells were significantly increased in primary and concomitant carcinoma in situ (CIS), p<0.0001, a highly malignant lesion which is the most significant single risk factor for disease progression. Further characterisation of the tumour immunophenotype identified IL-17+ cells as predominantly mast cells rather t…

EXPRESSIONPSORIASISBACILLUS-CALMETTE-GUERINCYTOKINESlcsh:Rlcsh:MedicinePROGRESSIONCOLORECTAL-CANCERIL-17INFLAMMATIONCARCINOMA IN-SITUlcsh:QRECURRENCElcsh:SciencePLoS ONE
researchProduct

Trattamento endovescicale alternativo al BCG nel carcinoma vescicale NMI a rischio intermedio o elevato

2013

Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer A shortage of BCG is foreseen till the end of 2013. Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available? In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice is radical cystectomy. Device-assisted therapies, although showing promising results, should be considered only for selected patients. In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG is available. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferably preceded by early …

Intravesical chemotherapy Bacillus Calmette-Guérin Non-muscle-invasive bladder cancer local hyperthermiaSettore MED/24 - Urologia
researchProduct

Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens

2006

Abstract Mycobacterium tuberculosis infects one-third of the global population and claims two million lives every year. Because memory CD8 T cells exhibit a high heterogeneity in terms of phenotype and functional characteristic, we investigated the frequency, phenotype, and functional properties of Ag85A epitope-specific HLA-A*0201 CD8 T cells in children affected by tuberculosis (TB) before and 4 mo after chemotherapy and healthy contact children. Using Ag85A peptide/HLA-A*0201 pentamer, we found a low frequency of blood peptide-specific CD8 T cells in tuberculous children before therapy, which consistently increased after therapy to levels detected in healthy contacts. Ex vivo analysis of…

MalePore Forming Cytotoxic ProteinsLEPROSYImmunologyEpitopes T-LymphocyteCD8-Positive T-LymphocytesBiologyTuberculinTUBERCULOSISEpitopeImmunophenotypingInterferon-gammaInterleukin 21Immune systemImmunophenotypingAntigenT-Lymphocyte SubsetsHLA-A2 AntigenHumansBACILLE CALMETTE-GUERINImmunology and AllergyCytotoxic T cellLymphocyte CountChildTuberculosis PulmonaryAntigens BacterialMembrane GlycoproteinsIFN-GAMMACOMPLEXHLA-A AntigensPerforinHIGH-FREQUENCIESMycobacterium tuberculosisINTRACELLULAR INFECTIONNatural killer T cellVirologyBOVIS BCGMICEChild PreschoolTuberculosis MeningealImmunologyFemaleImmunologic MemoryCD8RESPONSES
researchProduct

The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications

2021

Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal numbers of reactive TIL is indispensable. We have previously shown that expansion of tumor reactive TIL from primary bladder tumors and lymph node metastases is feasible. Here, we performed TIL harvesting from additional surgical specimens (additional 31 primary tumors and 10 lymph nodes) to generate a heterogenous cohort of 53 patients with bladder cancer (BC) to evaluate the tumor characteristics that lead to tumor-reactive TIL expansion. Amo…

Malelcsh:Immunologic diseases. AllergyCD3Immunologychemical and pharmacologic phenomenaBacillus Calmette–GuerinLymphocyte ActivationCancer VaccinesImmunotherapy AdoptiveCohort StudiesBasal (phylogenetics)Tumor Necrosis Factor Receptor Superfamily Member 9Lymphocytes Tumor-InfiltratingmedicineImmunology and AllergyHumansadoptive cellular immunotherapyLymph nodeCells CulturedAgedCell ProliferationOriginal Researchmolecular subtypesBladder cancerbiologyTumor-infiltrating lymphocytesbusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseMycobacterium bovismedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic Metastasistumor-infiltrating lymphocytesCancer researchbiology.proteinInterleukin-2bladder cancerFemaleLymphAntibodyUrotheliumbusinesslcsh:RC581-607CD8Frontiers in Immunology
researchProduct

Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked!

2015

An interesting series of 22 patients affected by severe systemic toxicity following bacillus Calmette-Guerin (BCG) intravesical adjuvant therapy for bladder cancer is presented in this issue of Inf...

Microbiology (medical)Malemedicine.medical_specialtyAntineoplastic AgentsGastroenterologySettore MED/24 - UrologiaInternal medicineparasitic diseasesmedicineAdjuvant therapyIntravesical bacillus Calmette-GuerinAnimalsHumansBacillus (shape)Mycobacterium bovisBladder cancerGeneral Immunology and Microbiologybiologybusiness.industryGeneral Medicinebiology.organism_classificationmedicine.diseaseMycobacterium bovisbladder cancer BCG toxicityInfectious DiseasesSystemic toxicityUrinary Bladder NeoplasmsBCG VaccinebusinessBCG vaccineInfectious diseases (London, England)
researchProduct

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct